Loading...
Novo Nordisk, a pharmaceutical company, argues that the side effects of its weight-loss drug, Ozempic, are well-known. The company plans to present new data from weight-loss and diabetes trials. Social media is fueling interest in weight loss drugs, particularly GLP-1s. Eli Lilly's GLP-1 drug has been approved by the FDA for weight loss, which will increase competition and potentially reduce costs for patients.
FDA approval of 2nd potent GLP-1 for treatment of obesity - Lilly’s drug Zepbound - will accelerate discounting as competition heats up, reducing costs and extending access to patients. A prior @AEIecon analysis captured magnitude of earlier discounts https://t.co/fNouMWWgk0 https://t.co/F07r1Hzr3k
$LLY A new heavyweight in #weightloss FDA approves Eli Lilly's blockbuster #GLP1 drug for weight loss $NVO https://t.co/1h3jDXdcqZ
Social media is fueling interest in weight loss drugs. Goldman Sachs' Chris Shibutani explains the focus on GLP-1s in #GSExchanges: https://t.co/btTC3omnL2 https://t.co/YNSG3hfAaN
Novo Nordisk to present new data from weight-loss, diabetes trials https://t.co/LbQP12Rf97 https://t.co/00ROG0XKuX
Ozempic side effects 'well-known,' Novo Nordisk argues https://t.co/ZPGvcW6mRS https://t.co/fmGkrtLvr4